Palamar Marcel, Grosu Iulia Dana, Schiller Adalbert, Petrica Ligia, Bodea Madalina, Sircuta Alexandru, Gruescu Elisabeta, Matei Oana Daniela, Tanasescu Maria Daniela, Golet Ionut, Bob Flaviu
Department of Internal Medicine II-Nephrology University Clinic, "Victor Babeș" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Centre for Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine, "Victor Babeș" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Biomedicines. 2024 Dec 28;13(1):48. doi: 10.3390/biomedicines13010048.
: Vitamin K deficiency in chronic kidney disease (CKD) could potentially occur due to multiple factors, leading to an increased risk of vascular and valvular calcifications. Vitamin K status can be indirectly assessed by measuring the blood levels of vitamin K-dependent proteins (VKDPs), such as matrix GLA protein (MGP). This study aims to examine the relationship between the levels of inactive MGP (dp-uc MGP) and the presence of valvular calcifications, as well as its association with mortality in hemodialysis patients. : We conducted a single-center study that included 45 CKD G5D patients (hemodialysis for 6 months to 10 years) followed up for 24 months. All patients have been assessed at baseline regarding cardiovascular disease (medical history, echocardiography). Moreover, using standard methods, we determined blood biochemistry, complete blood count, and matrix GLA protein. At 24 months of follow-up, we assessed all-cause mortality and cardiovascular mortality. : In the studied hemodialysis patients, mean dp-uc MGP was 3285.93 +/- 2092.85 pmol/L. Patients with valvular calcifications had higher levels of dp-uc MGP compared to those without (4521.08 +/- 2263.82 vs. 2487.53 +/- 1446.94 pmol/L, however not statistically significant). The presence and severity of valvular calcifications were significantly associated with the history of treatment with vitamin K antagonists ( < 0.05). After 24 months of follow-up, we found an all-cause mortality rate of 24.4%. The level of dp-uc MGP was higher in the group of patients that died (3884.81 +/- 2439.20 vs. 3133.09 +/- 1925.26 pmol/L, > 0.05). Patients with more than one valvular calcification on echocardiography had a significantly higher all-cause mortality risk ( = 0.04). In terms of traditional risk factors, we observed an increased risk of all-cause mortality in patients with a history of diabetes mellitus ( = 0.02) and aortic stenosis ( = 0.01). However, other cardiovascular markers, such as coronary heart disease and ejection fraction < 50%, did not have a statistically significant impact on mortality in our patients. : In our study, we found that vitamin K deficiency, measured indirectly using the level of VKDP, especially dp-uc MGP, is a predictor of valvular calcifications. Severe valvular calcifications, aortic stenosis, and the presence of diabetes mellitus are risk factors for all-cause mortality in hemodialysis patients.
慢性肾脏病(CKD)中维生素K缺乏可能由于多种因素而潜在发生,导致血管和瓣膜钙化风险增加。维生素K状态可通过测量维生素K依赖蛋白(VKDPs)的血液水平间接评估,如基质GLA蛋白(MGP)。本研究旨在探讨无活性MGP(dp - uc MGP)水平与瓣膜钙化的存在之间的关系,及其与血液透析患者死亡率的关联。
我们进行了一项单中心研究,纳入45例CKD G5D患者(血液透析6个月至10年),随访24个月。所有患者在基线时均已就心血管疾病(病史、超声心动图)进行评估。此外,我们使用标准方法测定了血液生化、全血细胞计数和基质GLA蛋白。在随访24个月时,我们评估了全因死亡率和心血管死亡率。
在研究的血液透析患者中,dp - uc MGP的平均水平为3285.93±2092.85 pmol/L。有瓣膜钙化的患者与无瓣膜钙化的患者相比,dp - uc MGP水平更高(4521.08±2263.82 vs. 2487.53±1446.94 pmol/L),但差异无统计学意义。瓣膜钙化的存在和严重程度与维生素K拮抗剂治疗史显著相关(<0.05)。随访24个月后,我们发现全因死亡率为24.4%。死亡患者组的dp - uc MGP水平更高(3884.81±2439.20 vs. 3133.09±1925.26 pmol/L,>0.05)。超声心动图显示有一处以上瓣膜钙化的患者全因死亡风险显著更高(=0.04)。就传统危险因素而言,我们观察到有糖尿病病史(=0.02)和主动脉狭窄(=0.01)的患者全因死亡风险增加。然而,其他心血管标志物,如冠心病和射血分数<50%,对我们患者的死亡率没有统计学显著影响。
在我们的研究中,我们发现使用VKDP水平,特别是dp - uc MGP间接测量的维生素K缺乏是瓣膜钙化的一个预测指标。严重瓣膜钙化、主动脉狭窄和糖尿病的存在是血液透析患者全因死亡的危险因素。